

Date: 12th February, 2020

To,
Listing Department,
BSE Limited
Floor 25, PJ Tower
Dalal Street,
Mumbai – 400 001

Script Code: 540359

Sub.: Outcome of the proceedings of the meeting of the Board of Directors of the Company

Dear Sirs,

This is to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 12th February, 2020, inter—alia, considered and approved the Unaudited Financial Results for quarter ended 31st December, 2019. The same has also been reviewed by the Audit Committee in its meeting held today.

A copy of the Statement of Unaudited Financial Results for the quarter ended 31st December, 2019, approved by the Board pursuant to Regulation 33 of the Securities And Exchange Board of India (LODR Regulations, 2015, is enclosed for your reference and record. A copy thereof has also been sent for publication as per the requirements. The meeting commenced at 2:00 pm and concluded at 7.00 pm.

We would like to submit that M/ s. B A Shah S R Mehta & Co., Statutory Auditors of Company have carried out limited review of Unaudited Financial Results for quarter ended 31st December, 2019 and Board has also taken on record their Limited Review Report on said Results.

Kindly take this on your records.

Thanking you,

Yours faithfully,

For, Parmax Pharma Limited


Yash J. Vora
Company Secretary and Compliance Officer



Statement of Standalone Unaudited Results for the Quarter & Nine Months ended 31.12.2019

(in Rs.)

Sr. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I.	Revenue from operations	69384878	55136220	18686906	165656070	87865033	120126358
II.	Other income	91943	197732	67258	476941	154168	481988
III.	Total Income (I+II)	69476821	55333952	18754164	166133011	88019201	120608346
IV.	Expenses						
	(a) Cost of materials consumed	33830775	29692519	9207125	82364743	37274521	39233109
	(b) Purchase of stock-in-trade	0	0	0	0	0	0
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	2577986	-2483059	-1295207	4149121	14510330	12174762
	(d) Employee benefits expense	7372508	7963281	5352005	22351538	15471167	20754610
	(e) Finance Costs	116779	95396	37035	360875	373718	325496
	(f) Depreciation and amortisation expense	2170283	2020750	2595586	6359296	7743023	10302507
	(g) Other expenses*	13239244	12237788	5771995	37425543	20491442	36836606
	Total expenses (IV)	59307575	49526675	21668539	153011116	95864201	119627090
V	Profit/(Loss) from operations before exceptional items and tax (I-IV)	10169246	5807277	-2914375	13121895	-7845000	981256
VI	Exceptional Items	0	0	0	0	0	0
VII	Profit/ (Loss) before tax (V-VI)	10169246	5807277	-2914375	13121895	-7845000	981256
VIII	Tax expense:						
	(1) Current tax	0	0	0	0	0	750000
	(2) Deferred tax	0	0	0	0	0	(555,741)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	10169246	5807277	-2914375	13121895	-7845000	786997
X	Profit/(loss) from discontinued operations						
XI	Tax expense of discontinued operations	0	0	0	0	0	0
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0	0	0	0	0	0
XIII	Profit (Loss) for the period (IX+XII)	10169246	5807277	-2914375	13121895	-7845000	786997
XIV	Other Comprehensive Income						
	A. (i) Items that will not be reclassified to profit or loss						
	(ii) Income tax relating to items that will not be reclassified to profit or loss	0	0	0	0	0	0
	B. (i) Items that will be reclassified to profit or loss						
	(ii) Income tax relating to items that will be reclassified to profit or loss						
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	10169246	5807277	-2914375	13121895	-7845000	786997
XVI	Paid-up equity share capital (Face Value Rs 10)	37413000	37413000	37413000	37413000	37413000	37413000
XVII	Earnings per share (for continuing operation & discontinuing operation) (of Rs. 10/- each):						
	(a) Basic	0.27	1.55	-0.78	3.51	-2.10	0.21
	(b) Diluted						

Notes:

1. The above unaudited financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 12.02.2020.
 2. The Statutory Auditors have carried out a Limited Review of the Unaudited standalone results of the quarter and nine months ended 31st December, 2019
 3. The Company is operating in single (pharmaceutical) segment, so above results are for single segment only.
 4. Statement of Unaudited Financial Results of the company for the quarter and nine months ended 31st December, 2019, in the prescribed format under Schedule III of Companies Act, 2013
 5. The figures for the previous period have been regrouped wherever necessary.
- * The Company has decided to gradually write off its all Preliminary and Pre-operative expenses which are forming the part of Balance Sheet accordingly Company has written off Rs. 9,90,350/- during this quarter under review and it is forming part of Other Expenses.

FOR, PARMAX PHARMA LIMITED



Alkesh Gosalia
Managing Director (Finance and Operations)



Place Hadamtala (Rajkot)
Date: 12.02.2020

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. F.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

Auditor's Limited Review Report On Unaudited Financial Results

To

The Board of Directors,
PARMAX PHARMA LIMITED

We have reviewed the accompanying statement of standalone unaudited financial results of **PARMAX PHARMA LTD** ("the Company") for the quarter and nine months ended 31st December 2019 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This Statement is the responsibility of the Company's management and has been approved by the Board of Directors on **12th February 2020**. Our responsibility is to issue a report on this Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian Accounting Standards (IND AS) prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the



Head Office:
209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:
302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:
(O) 0281-2468261
(M) 09427564149
(E) bassrmco.office@gmail.com
Or
mbshah_31@hotmail.com

B A SHAH S R MEHTA & Co.

Chartered Accountants

Partner
Shailesh R Mehta
B.Com. F.C.A.

M.No. 038000

Partner
Malay B Shah
B.Com. F.C.A.

M. No. 159526

Partner
Zarna M Shah
M.Com. F.C.A. DISA
(Information Systems Audit)
M. No. 144246

information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Rajkot

Date : 12.02.2020



For **B. A. SHAH S R MEHTA & Co.**
Chartered Accountants
FRN NO : 128796W

A handwritten signature in blue ink that reads "Malay B Shah".

MALAY B SHAH

Partner

M. No. 159526

UDIN : 20159526AAAAAH9755

Head Office:

209-Sapphire Complex, IInd Floor
21/25-B New Jagnath Plot,
Dr.Yagnik Road
RAJKOT- 360 001
(GUJARAT)

Branch Office:

302-Vedant Complex,
7/B Kalpana Society,
C.G.Road, Navrangpura,
AHMEDABAD - 380 009
(GUJARAT)

Electronic Address:

(O) 0281-2468261

(M) 09427564149

(E) bassrmco.office@gmail.com

Or

mbshah_31@hotmail.com